טוען...
Initial Testing (Stage 1) of MK-8242, a Novel MDM2 Inhibitor, by the Pediatric Preclinical Testing Program
BACKGROUND: MK-8242 is an inhibitor of MDM2 that stabilizes the tumor suppressor TP53 and induces growth arrest or apoptosis downstream of TP53 induction. PROCEDURES: MK-8242 was tested against the PPTP in vitro cell line panel at concentrations from 1.0 nM to 10.0 μM and against the PPTP in vivo xe...
שמור ב:
| הוצא לאור ב: | Pediatr Blood Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5657425/ https://ncbi.nlm.nih.gov/pubmed/27238606 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.26064 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|